
Vectura, the Chippenham firm pioneering new ways of treating asthma and lung diseases, is to merge with a smaller rival as it continues to develop into one of the UK’s leading specialist pharmaceutical firms. Vectura’s £440m recommended tie-up with London-based Skyepharma will create a £1bn company which will generate sales of more than £150m...